共 30 条
- [13] Fleming ID, 1997, AJCC Cancer Staging Manual, V5th, P127
- [17] TOXICITY AND RESPONSE CRITERIA OF THE EASTERN-COOPERATIVE-ONCOLOGY-GROUP [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1982, 5 (06): : 649 - 655
- [18] Treatment Rationale and Study Design for the PointBreak Study: A Randomized, Open-label Phase III Study of Pemetrexed/Carboplatin/Bevacizumab Followed by Maintenance Pemetrexed/Bevacizumab Versus Paclitaxel/Carboplatin/Bevacizumab Followed by Maintenance Bevacizumab in Patients with Stage IIIB or IV Nonsquamous Non-Small-Cell Lung Cancer [J]. CLINICAL LUNG CANCER, 2009, 10 (04) : 252 - 256
- [19] Treatment rationale and study design for a phase III, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer [J]. BMC CANCER, 2010, 10